Articles tagged "Rejection"

2019 American Transplant Congress
Involvement of Genetic Variation and Related Gene Expression Changes on Acute Rejection in Renal Transplant Recipients
H. Hwang¹, J. Seo¹, J. Kim¹, Y. Kim¹, J. Moon¹, K. Jeong¹, C. Kim², J. Park³, B. Chung⁴, Y. Kim⁵, S. Lee¹
¹Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea, Republic of, ²Division of Nephrology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic of, ³Department of Surgery, Samsung Medical Center, Seoul, Korea, Republic of, ⁴Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea, Seoul, Korea, Seoul, Korea, Republic of, ⁵Division of Nephrology, Department of Internal Medicine, College of Medicine, Inje University, Pusan, Korea, Republic of
*Purpose: Acute rejection (AR) is one of the major risk factors for renal allograft loss. The effect of genetic factors on the transplant outcomes has…
2019 American Transplant Congress
Increased Number of Intragraft FoxP3+ T Cells is Strongly Correlated with Decreased Graft Survival in Chronic Active Antibody Mediated Rejection
K. Sablik¹, K. Jordanova², M. Clahsen-van Groningen¹, M. Betjes¹
¹Erasmus MC, Rotterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands
*Purpose: Chronic-active antibody-mediated rejection (c-aABMR) is the most important cause of late renal allograft failure. However, renal inflammation and rate of loss of renal allograft…
2019 American Transplant Congress
Respiratory Viral Infections and Patient Outcomes in Solid Organ Transplant Recipients
M. Gonzalez¹, A. Vostal¹, N. Darling², C. Papastamelos², M. Natarajan³, P. Kumar³, J. Timpone³
¹Internal Medicine, MedStar Georgetown University Medical Center, Washington, DC, ²School of Medicine, Georgetown University, Washington, DC, ³Infectious Disease, MedStar Georgetown University Medical Center, Washington, DC
*Purpose: Community acquired respiratory viral infections (RVI) have been associated with significant morbidity and mortality in solid organ transplant recipients (SOTR). Acute rejection and allograft…
2019 American Transplant Congress
Alteration of Myocardial Velocities and T1 Times in Patients with Acute Cellular Rejection during First Year Post Heart Transplant
R. Sarnari, A. Ruh, M. Abbasi, J. Blaisdell, R. Dolan, J. Wilcox, S. Khan, E. Vorovich, J. Rich, A. Anderson, C. Yancy, J. Carr, M. Markl, K. Ghafourian
Northwestern University, Chicago, IL
*Purpose: We hypothesize that acute cellular rejection (ACR) episodes during the first year post heart transplant (HTx) may lead to structural and functional alterations of…
2019 American Transplant Congress
Soluble Fibrinogen-Like Protein 2 Regulates MDSCs Differentiation and Function in Allograft Immunity
C. Yang
Urology, Zhongshan Hospital, Fudan University, Shanghai, China
*Purpose: Soluble fibrinogen-like protein 2 (sFGL2) is a novel immunoregulatory molecule, secreted mainly by regulatory T cells. CD11b+ Gr1+ myeloid-derived suppressor cells (MDSCs) are an…
2019 American Transplant Congress
Inpatient versus Outpatient Management of Hyperglycemia in Post-Transplant Patients Following High Dose Steroid Pulses for Acute Rejection
J. L. Wisniewski¹, W. Bruneau², E. A. Cohen²
¹University of Connecticut, School of Pharmacy, Storrs, CT, ²Yale New Haven Hospital, New Haven, CT
*Purpose: Acute cellular rejection (ACR) occurs in approximately ten percent of all transplant patients and is typically treated with multiple infusions of high-dose steroids (HDS).…
2019 American Transplant Congress
Efficacy and Safety of Alemtuzumab versus Basiliximab Induction in Lung Transplantation
J. Choe, J. Au, A. Diamond, C. Ruggia-Check, S. Sehgal, F. Cordova, N. Shigemura, S. Keshavamurthy, Y. Toyoda
Temple University Hospital, Philadelphia, PA
*Purpose: Minimal literature exists regarding alemtuzumab for induction in lung transplantation but is the preferred agent at Temple University Hospital (TUH). Basiliximab is reserved for…
2019 American Transplant Congress
Immediate Post Reperfusion In Vivo Transcriptional Responses of Individual Human Renal Allograft Cell Populations to Circulating Anti-Angiotensin II Type I Receptor Antibody
C. M. Castro -Rojas¹, N. Salomonis², K. Chetal², R. R. Alloway³, E. Woodle³, D. A. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, ²Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, ³Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH
*Purpose: Pre-existing anti-angiotensin II type I receptor (AT1R) antibodies can be a significant driver of allograft rejection. Indeed, prior work has shown that AT1R antibodies…
2019 American Transplant Congress
Long Term Follow-Up of the Use of Checkpoint Inhibitors in Kidney Transplant Recipients
K. Venkatachalam, R. Delos Santos, T. Alhamad
Transplant nephrology, Washington University, St. Louis, MO
*Purpose: To report the long term impact of check point inhibitors in patient and allograft survival among kidney transplant recipients.*Methods: We report follow up of…
2019 American Transplant Congress
IgG4 Subclass Class 2 Donor Specific Antibody (DSA) is Associated with Subclinical Rejection in Stable Pediatric Liver Transplant (LT) Recipients with Normal Liver Tests
A. Jackson¹, S. Kanaparthi², B. Burrell³, D. Lucas⁴, R. Vega⁴, A. J. Demetris⁵, S. Feng⁶
¹Surgery, Duke University, Durham, NC, ²The Immune Tolerance Network, Bethesda, MD, ³Immune Tolerance Network, Bethesda, MD, ⁴Medicine, Johns Hopkins University, Baltimore, MD, ⁵Pathology, University of Pittsburgh, Pittsburgh, PA, ⁶Surgery, University of California San Francisco, San Francisco, CA
*Purpose: DSA is a known biomarker of allograft rejection, yet injury phenotype and potential differ across organs. Among pediatric LT recipients entering iWITH (NCT01638559), an…